Stomach Cancer Trial, Recruiting (NCT04809025)

Stomach Cancer Trial, Recruiting NCT04809025 Sponsor: Fudan University Condition: Stomach Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT04809025 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Stomach Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 18 to 75 years old
People who have been diagnosed with primary gastric (stomach) adenocarcinoma, confirmed by a tissue biopsy taken within the last 12 months
People who are able to provide written consent to participate
People who are planned to have surgery to fully remove the stomach tumour (known as radical R0 gastrectomy)

Who may not be able to join:

People who are pregnant or breastfeeding
People whose stomach cancer cannot be surgically removed
People who have serious heart, lung, kidney, or liver disease, or who have poorly controlled high blood pressure, diabetes, mental health conditions, or other serious illnesses
People who are considered unlikely to follow the trial's requirements consistently
People who have received any cancer treatment — including chemotherapy, biological therapy, radiation, or immunotherapy — within 4 weeks before or after enrolling in the trial
People who have had an organ transplant, require long-term use of immune-suppressing medications, or have an autoimmune disease

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 6 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Dazhi Xu, PHD, MD, Fudan University

Phone: (+86) 021-38196215

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04809025

Sponsor: Fudan University

Phase: Not Applicable

Status: Recruiting

Condition: Stomach Cancer

Trial contact: (+86) 021-38196215

More information: https://clinicaltrials.gov/study/NCT04809025

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 18 to 75 years old
People who have been diagnosed with primary gastric (stomach) adenocarcinoma, confirmed by a tissue biopsy taken within the last 12 months
People who are able to provide written consent to participate
People who are planned to have surgery to fully remove the stomach tumour (known as radical R0 gastrectomy)

Who may not be able to join:

People who are pregnant or breastfeeding
People whose stomach cancer cannot be surgically removed
People who have serious heart, lung, kidney, or liver disease, or who have poorly controlled high blood pressure, diabetes, mental health conditions, or other serious illnesses
People who are considered unlikely to follow the trial's requirements consistently
People who have received any cancer treatment — including chemotherapy, biological therapy, radiation, or immunotherapy — within 4 weeks before or after enrolling in the trial
People who have had an organ transplant, require long-term use of immune-suppressing medications, or have an autoimmune disease

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 6 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Fudan University

Registry

ClinicalTrials.gov

Start date

24 May 2021

Est. completion

1 September 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Diagnostic accuracy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov